Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 29 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Magis-Pharma from Antwerpen, company number BE0644784239, closed financial year 2025 with a result of € -374,469 after tax. For that financial year Magis-Pharma recorded revenue of € 14.7 million and equity of € 247,993. Compared with financial year 2024, the result moved from € -1.5 million to € -374,469. The company made a loss. The buffer shrank hard: equity is 60 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 247,993
▼ 60% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -374,469
▲ 74 % less loss than in 2024
Profit after tax over the fiscal year.
€ 93,370
▼ 88% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -615,214.
People and assets in 2025
55.2
▲ 4.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 3.6 million
▼ 3% vs 2024
€ 64,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 160,139
▼ 62% vs 2024
Of which on lease € 109,631.
Debts at end 2025
€ 4.3 million
▲ 130% vs 2024
€ 134,990 is repaid this year. At this pace the long-term loan is gone in ≈ 32 years.
€ 2.5 million
▼ 23% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 88 days on average.
€ 616,181
▼ 25% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 11,977,209 | € 12,156,578 | € 14,098,349 | € 14,703,063 | ▲ 4% |
| Profit after taxes | € 35,955 | € -275,400 | € -1,456,750 | € -374,469 | ▲ € 1.1 million |
| Equity | € 2,061,141 | € 1,785,741 | € 622,462 | € 247,993 | ▼ 60% |
| Total debts | € 3,278,011 | € 5,746,321 | € 10,984,808 | € 12,300,980 | ▲ 12% |
| Cash | € 100,813 | € 470,439 | € 776,708 | € 93,370 | ▼ 88% |
| Land & buildings | - | - | € 261,437 | € 364,472 | ▲ 39% |
| Retained profit | € 1,265,426 | € 990,026 | € -240,744 | € -615,214 | ▼ € 374,469 |
| Bank debt | € 644,150 | € 704,672 | € 1,883,099 | € 4,339,441 | ▲ 130% |
| Balance sheet total | € 5,339,151 | € 7,532,061 | € 11,607,270 | € 12,548,973 | ▲ 8% |
| Employees (FTE) | 14 | 16.6 | 50.6 | 55.2 | ▲ 4.6 |
Key figures of Magis-Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Magis-Pharma?
What happened at Magis-Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Green Monkey BV stepped down as director. NBB
- Paulus de Vogel stepped down as director. NBB
- Jeroen van der Hamsvoort stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 374,469. Source: NBB ↗
- Green Monkey BV became a director. NBB
- Paulus de Vogel became a director. NBB
- Jeroen van der Hamsvoort became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 35,955 profit in 2022 to € 374,469 loss in 2025.
Paid € 101,012 in corporate taxes since 2022.
Best year ever: 2022, with € 35,955 profit.
Pays suppliers within 88 days on average.
A new publication or filing at Magis-Pharma? We notify you, reason included.
Follow Magis-PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Magis Pharma, Magis Pharma Group comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Magis-PharmaThe shares are held by Magis Pharma (100%) and Magis Pharma Group (100%).
Directors
According to the 2025 annual accounts
Managing director · represented by Christophe Bouvry
Also active at: PARCHIM, isomasters, Magis Pharma Group
since 2026 · until 2032
Paulus de Vogel
Director
since 2026 · until 2032
since 2026 · until 2032
Shareholders
100%
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Neerlandweg 24
2610 Antwerpen
Oostmalsebaan 1C box 5
2960 Brecht
Active since 22 December 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Google Workspace
Hosting
NEDZONE-AS, NL
Website info
Features
Security
Details
- Company number
- 0644.784.239
- VAT number
- BE 0644.784.239
- Registered office
- Neerlandweg 24, 2610 Antwerpen
- Names & denominations
- Magis-Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 22 December 2015
- Peppol
- Active · Active since 4 Nov 2025
- Contact
- magis-pharma.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van andere chemische producten, neg
Vervaardiging van geneesmiddelen
Activiteiten van verpakkingsbedrijven
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van andere organische chemische basisproducten
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering